Chul Kim

@ASCO LUNG ABSTRACTS MEGA-THREAD ⭐️I've said it before; #ASCO26 is like a giant music festival - the @coachella of oncology 🎵You have the headliners [plenaries], acts on the main stages [halls B & D], & indie gems on the side [posters] 🎗️My PERSONAL list of the MOST interesting abstracts and WHY I think they are great! 🧵

🫁 As you build your schedule for #ASCO26, don’t miss (or 🔖 bookmark to watch later) several interesting #LungCancer abstracts being presented outside the lung cancer tracks. Some highlights include ⬇️ 1️⃣ ctDNA Clinical Science Symposium: FLAME: osimertinib ± chemotherapy in EGFRm NSCLC with persistent ctDNA+ after 3 weeks on 1L osimertinib 2️⃣ #GlobalOnc #CareDelivery Clinical Science Symposium: Low-dose pembrolizumab + chemotherapy in 1L advanced NSCLC 3️⃣ CNS Tumors Oral Abstracts: ESAONA: asandeutertinib vs. osimertinib in 1L EGFRm NSCLC with brain metastases #LCSM #ASCO26 @ASCO @OncBrothers @OncoAlert

Excited to see the full presentation #ASCO26 by @LaurenByersMD on ABBV-706, a SEZ6 ADC with promising activity in relapsed/refractory #SCLC! 📊 Key results: • ORR 82% in 2L pts (1.8 mg/kg) ‼️ • mOS 14.3 mo in 2L monotherapy • 15-mo OS rate: 50% • Combo w/ budigalimab (anti-PD-1): ORR 55%, mPFS 8.1 mo, no new safety signals ⭐️No treatment-related deaths. No pneumonitis with combo! (small n) An ADC target in SCLC worth watching !! 👀 @drshieldsmd @ASCO #lcsm @alissajcooper

Pleasant Surprise from #ASCO26 Abstract 8002 (LORIN): neoadjuvant lorlatinib in stage III ALK+ NSCLC hits a pCR of 46.9% and MPR of 81.3% — pathologic responses we rarely see with neoadjuvant TKIs. 75% of initially unresectable pts converted to surgery. Targeted neoadj earning its seat. #LCSM @OncoAlert @OncBrothers @StephenVLiu @Jani_Chinmay @asco @myESMO @glopesmd @SylvesterCancer @latinamd @COlazagasti

Join us tomorrow for a webinar on clinical trials and emerging therapies in thymic epithelial tumors, featuring an outstanding panel of experts discussing advances in targeted therapy, immunotherapy, ADCs, and radiotherapy! Register: bit.ly/4dELVTG @Itmig_society

🧵 CROWN 7-Year Update: Lorlatinib in 1L ALK+ NSCLC: the longest PFS ever reported in advanced NSCLC keeps getting longer!!! #ASCO26 🫁 Abstracts! Presenter: @TonyMok9 Key takeaways: 👇 @ALKPositiveinc 1) 1/ 📈 Median PFS STILL not reached at 7 years. • 7-yr PFS rate: 55% (lorlatinib) vs 3% (crizotinib), HR 0.19 • 44% of pts STILL on lorlatinib vs just 3% on crizotinib

Excited to be selected as an #ASCO26 Featured Voice, along with esteemed colleagues and friends!! It's going to be an incredible meeting! From practice-changing lung cancer trials to landmark plenary sessions across oncology, there is SO much to cover. 🫁 Can't wait to share the science, the data, and what it means for our patients. Follow along! 🧵👇 @lungoncdoc @ASCO #lcsm graphics: @ADesaiMD, @Latinamd

I’m looking forward to speaking at #OncForum2026 at 5:30 PM CT on May 31! I'll be joined by Drs. @DasMillie11, @BalazsHalmosMD, and @therealoncdoc to discuss lung cancer updates from #ASCO26 & how to translate them into practice. Register here: cvent.me/QyA8Nx?rt=9ExY…

🚨We are recruiting! Looking for a passionate post-doc who can take the lead on some new projects in the lab 🔬 see below for details! @UTMDAnderson jobs.mdanderson.org/search/jobdeta…

Time to focus on.. the thymus! Relevant experience - principally on thymic carcinomas (28/30 pts) w intriguing signals of activity but also some irAE safety concerns Would just be careful not to interpret more broadly for thymomas where safety concerns had been very prominent re severe irAEs

🧵1/3🔥@OncoAlert Hot off the press. ⭐️My co-authors & I are excited to share this just published paper @ClinicalLung on: ✅#RealWorld Assessment of #Efficacy & #Toxicity of #Immune #CheckPointInhibitors (#ICI) in Advanced #Thymic #EpithelialTumors. 👇🏻 sciencedirect.com/science/articl…

@LauraAlderMD @StephenVLiu Thanks Laura. Yes another exciting ASCO this year. Hope to see you at ASCO!

@chulkimMD @StephenVLiu Congratulations, Chul!! 👏 Will be lots of terrific data to discuss!

Honored to serve as Co-Chair for Best of ASCO Washington DC, a free CME-accredited meeting featuring highlights from the ASCO Annual Meeting We have a great line-up of speakers who will discuss the abstracts with the greatest clinical impact Register: bit.ly/4uR0n1E

@LauraAlderMD @ASCO Congratulations!

Honored to serve on @ASCO's expert panel for the Stage IV Non-Small Cell Lung Cancer Living Guidelines! Lung cancer care is evolving rapidly, and I'm excited to work alongside incredible colleagues to ensure clinicians have the most current, evidence-based guidance at their fingertips. 🫁✨ #LCSM #NSCLC

Join us for a webinar on updates in clinical guidelines for thymic tumors, featuring thought leaders Drs. Gregory Riely (@RielyMD), Nicolas Girard (@nicogirardcurie), Vincent Fang & Clémence Basse. 📅 May 20, 9–10 AM EDT Register: bit.ly/4diIq6s @Itmig_society

🚨New Pub 🧵1) Our new study in #TranslationalLungCancerResearch explores a combination strategy for #KRASG12C-mutant #NSCLC: sotorasib plus trastuzumab deruxtecan. In preclinical models, the combination produced deeper and more durable regressions than either agent alone. tlcr.amegroups.org/article/view/1…